Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 18Gynecologic 4Head & Neck 2Dermatologic 2Breast 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × CP protocol × Head & Neck × Clear all
NCT06062602 2023-10-06

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Presage Biosciences

Phase EARLY_PHASE1 Completed
15 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡